207 related articles for article (PubMed ID: 37819557)
1. Reevaluating tau reduction as a therapeutic approach for tauopathies: Insights and perspectives.
Sun X; Ogbolu VC; Baas PW; Qiang L
Cytoskeleton (Hoboken); 2024 Jan; 81(1):57-62. PubMed ID: 37819557
[TBL] [Abstract][Full Text] [Related]
2. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
Venkatramani A; Panda D
Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
[TBL] [Abstract][Full Text] [Related]
3. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
Bakota L; Ussif A; Jeserich G; Brandt R
Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
[TBL] [Abstract][Full Text] [Related]
4. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
5. Tau Does Not Stabilize Axonal Microtubules but Rather Enables Them to Have Long Labile Domains.
Qiang L; Sun X; Austin TO; Muralidharan H; Jean DC; Liu M; Yu W; Baas PW
Curr Biol; 2018 Jul; 28(13):2181-2189.e4. PubMed ID: 30008334
[TBL] [Abstract][Full Text] [Related]
6. The homologous carboxyl-terminal domains of microtubule-associated protein 2 and TAU induce neuronal dysfunction and have differential fates in the evolution of neurofibrillary tangles.
Xie C; Miyasaka T; Yoshimura S; Hatsuta H; Yoshina S; Kage-Nakadai E; Mitani S; Murayama S; Ihara Y
PLoS One; 2014; 9(2):e89796. PubMed ID: 24587039
[TBL] [Abstract][Full Text] [Related]
7. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
8. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
[TBL] [Abstract][Full Text] [Related]
9. Studying Microtubule Dynamics in Human Neurons: Two-Dimensional Microtubule Tracing and Kymographs in iPSC- and SH-SY5Y-Derived Neurons for Tau Research.
Allroggen N; Breuer H; Bachmann S; Bell M; Zempel H
Methods Mol Biol; 2024; 2754():561-580. PubMed ID: 38512690
[TBL] [Abstract][Full Text] [Related]
10. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
[TBL] [Abstract][Full Text] [Related]
11. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
12. Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Hamano T; Shirafuji N; Yen SH; Yoshida H; Kanaan NM; Hayashi K; Ikawa M; Yamamura O; Fujita Y; Kuriyama M; Nakamoto Y
Neurobiol Aging; 2020 May; 89():41-54. PubMed ID: 31982202
[TBL] [Abstract][Full Text] [Related]
13. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
Quraishe S; Cowan CM; Mudher A
Mol Psychiatry; 2013 Jul; 18(7):834-42. PubMed ID: 23587881
[TBL] [Abstract][Full Text] [Related]
14. Neurofibrillary degeneration can be arrested in an in vivo cellular model of human tauopathy by application of a compound which inhibits tau filament formation in vitro.
Hall GF; Lee S; Yao J
J Mol Neurosci; 2002 Dec; 19(3):253-60. PubMed ID: 12540050
[TBL] [Abstract][Full Text] [Related]
15. Altered Proteostasis in Neurodegenerative Tauopathies.
Papanikolopoulou K; Skoulakis EMC
Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
[TBL] [Abstract][Full Text] [Related]
16. [The microtubule-associated protein tau in neurodegenerative diseases. Tauopathies].
Sánchez MP; Alvarez-Tallada V; Avila J
Rev Neurol; 2001 Jul 16-31; 33(2):169-77. PubMed ID: 11562878
[TBL] [Abstract][Full Text] [Related]
17. Tau, tau kinases, and tauopathies: An updated overview.
Montalto G; Ricciarelli R
Biofactors; 2023; 49(3):502-511. PubMed ID: 36688478
[TBL] [Abstract][Full Text] [Related]
18. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
19. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
[TBL] [Abstract][Full Text] [Related]
20. Knockin' on heaven's door: Molecular mechanisms of neuronal tau uptake.
De La-Rocque S; Moretto E; Butnaru I; Schiavo G
J Neurochem; 2021 Mar; 156(5):563-588. PubMed ID: 32770783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
